草药（枣独泻肝丸）对轻度认知障碍患者生活质量的影响：与随机对照试验并行的成本效益分析

The effects of herbal medicine (Jujadokseo-hwan) on quality of life in patients with mild cognitive impairment: Cost-effectiveness analysis alongside randomized controlled trial.

作者信息

Lee Ji-Eun, Kang Hyung Won, Jung Sun-A, Lee So-Young, Kim Ju Yeon, Lee Da Eun, Jeong Jin-Hyung, Jung In Chul, Cho Eun

机构信息

College of Pharmacy, Sookmyung Women's University, Seoul, Republic of Korea.

Department of Neuropsychiatry, College of Oriental Medicine, Wonkwang University, Iksan, Republic of Korea.

出版信息

Integr Med Res. 2023 Mar;12(1):100914. doi: 10.1016/j.imr.2022.100914. Epub 2022 Dec 22.

DOI:10.1016/j.imr.2022.100914

PMID:36632128

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9826841/

Abstract

BACKGROUND

Mild cognitive impairment (MCI), the early stage of dementia, requires effective intervention for symptom management and improving patients' quality of life (QoL). Jujadokseo-hwan (JDH) is a Korean herbal medicine prescription used to improve MCI symptoms, such as memory deficit. This study evaluates the improvement in QoL through JDH. Alongside a clinical trial, it estimates the cost-effectiveness of JDH, compared to placebo, for MCI over 24 weeks.

METHODS

Changes in QoL were measured using the EuroQol-5 Dimensions (EQ-5D) and Korean version QoL-Alzheimer's Disease (KQOL-AD). Direct medical and non-medical costs were surveyed and incremental cost-effectiveness ratios (ICER) per QALY for JDH were produced.

RESULTS

In total, 64 patients were included in the economic evaluation (n = 35 in JDH, n = 29 in placebo). In the JDH group, EQ-5D and KQOL-AD improved by 0.020 (p = .318) and 3.40 (p = .011) over 24 weeks, respectively. In the placebo group, they increased by 0.001 (p=.920) and 1.07 (p=.130), respectively. The ICER was KRW 76,400,000 per QALY and KRW 108,000 per KQOL-AD for JDH, compared to the placebo group.

CONCLUSION

JDH is not considered a cost-effective treatment option compared with placebo; however, it positively affects QoL improvement in patients with MCI.

摘要

背景

轻度认知障碍（MCI）作为痴呆症的早期阶段，需要有效的干预措施来管理症状并改善患者的生活质量（QoL）。枣独泻肝丸（JDH）是一种用于改善MCI症状（如记忆缺陷）的韩方草药处方。本研究评估了JDH对生活质量的改善情况。除了临床试验外，还估计了JDH与安慰剂相比，在24周内治疗MCI的成本效益。

方法

使用欧洲五维健康量表（EQ-5D）和韩国版阿尔茨海默病生活质量量表（KQOL-AD）来测量生活质量的变化。调查了直接医疗和非医疗成本，并计算了JDH每获得一个质量调整生命年（QALY）的增量成本效益比（ICER）。

结果

共有64名患者纳入经济评估（JDH组35例，安慰剂组29例）。在JDH组中，EQ-5D和KQOL-AD在24周内分别改善了0.020（p = 0.318）和3.40（p = 0.011）。在安慰剂组中，它们分别增加了0.001（p = 0.920）和1.07（p = 0.130）。与安慰剂组相比，JDH每QALY的ICER为76,400,000韩元，每KQOL-AD的ICER为108,000韩元。